Journal of Clinical Oncology, Vol 1, 255-262, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone

MA Knowling, AR Harwood and DE Bergsagel

Patients with solitary osseous plasmacytomas (SOP) differ from those with extramedullary plasmacytomas (EMP) in that they are younger and the proportion of males is smaller. The median survival of the two groups is similar: 86.4 mo for SOP, and 100.8 mo for EMP. Progression- free survival, however, is much better for EMP. Only five EMP patients have progressed following initial radiation therapy: one developed a single bony lesion, two progressed to multiple myeloma, and two developed multiple EMP. Thus, 71% of EMP patients are progression free at 10 yr, and most deaths do not result from plasma cell neoplasia. In contrast, 13 SOP patients have progressed to develop additional osteolytic lesions, so that only 16% of SOP patients are progression free at 10 yr; death resulted from progression to multiple myeloma in most of these patients. In EMP patients the occurrence of involved lymph nodes at the time of diagnosis in seven, and initial relapse in regional nodes in three, suggest that consideration should be given to including regional lymph nodes in the radiation fields used to treat these patients.

This article has been cited by other articles:

				G. C. Ooi, J. C.-S. Chim, W.-Y. Au, and P.-L. Khong Radiologic manifestations of primary solitary extramedullary and multiple solitary plasmacytomas. Am. J. Roentgenol., March 1, 2006; 186(3): 821 - 827. [Abstract] [Full Text] [PDF]

				V J Michalaki, J Hall, J M Henk, C M Nutting, and K J Harrington Definitive radiotherapy for extramedullary plasmacytomas of the head and neck Br. J. Radiol., October 1, 2003; 76(910): 738 - 741. [Abstract] [Full Text] [PDF]

				S. Kumar, R. Fonseca, A. Dispenzieri, M. Q. Lacy, J. A. Lust, L. Wellik, T. E. Witzig, M. A. Gertz, R. A. Kyle, P. R. Greipp, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma Blood, March 1, 2003; 101(5): 1715 - 1717. [Abstract] [Full Text] [PDF]

				E Ahamed, L M Samuel, and J E Tighe Extramedullary plasmacytoma of the eyelid Br. J. Ophthalmol., February 1, 2003; 87(2): 244 - 245. [Full Text]

				R. V. Datta, T. Daskalakis, H. Adler, and H. Lehman Unusual Presentations of Uncommon Tumors: Case 3. Giant Cell Plasmacytoma Presenting as an Intraperitoneal Mass J. Clin. Oncol., May 1, 2002; 20(9): 2405 - 2406. [Full Text] [PDF]

				M. A. Dimopoulos, L. A. Moulopoulos, A. Maniatis, and R. Alexanian Solitary plasmacytoma of bone and asymptomatic multiple myeloma Blood, September 15, 2000; 96(6): 2037 - 2044. [Abstract] [Full Text] [PDF]

				D. R. Sariya, N. A. Jambhekar, V. Srinivas, S. H. Advani, and K. A. Dinshaw A Clinicopathologic Study of Solitary Myeloma: An 11-Year Study International Journal of Surgical Pathology, October 1, 1999; 7(4): 243 - 250. [Abstract] [PDF]

				R. AFRA, D. L. BOARDMAN, J. M. KABO, and J. J. ECKARDT Avulsion Fracture of the Lesser Trochanter as a Result of a Primary Malignant Tumor of Bone. A Report of Four Cases J. Bone Joint Surg. Am., September 1, 1999; 81(9): 1299 - 304. [Full Text]

				L. A. Moulopoulos and M. A. Dimopoulos Magnetic Resonance Imaging of the Bone Marrow in Hematologic Malignancies Blood, September 15, 1997; 90(6): 2127 - 2147. [Full Text] [PDF]